drugset
drugset / Trial / NCT00635765

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00635765 ↗

Phase 3 Completed 63 enrolled Ambrilia Biopharma, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety profile of C2L-OCT-01 PR for up to an additional 96-week period in acromegalic patients who completed the C2L-OCT-01 PR-301 study.

Timeline

Start
2007-10
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Octreotide Peptide 30 mg Intramuscular

Indications

acromegaly